• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

MAbs . Selection and verification of antibodies against the cytoplasmic domain of M2 of influenza, a transmembrane protein

tetano

Editor, Senior Moderator
MAbs


. Jan-Dec 2020;12(1):1843754.
doi: 10.1080/19420862.2020.1843754.
Selection and verification of antibodies against the cytoplasmic domain of M2 of influenza, a transmembrane protein


Nileena Velappan[SUP] 1 [/SUP], Sofiya Micheva-Viteva[SUP] 1 [/SUP], Samantha H Adikari[SUP] 1 [/SUP], Geoffrey S Waldo[SUP] 1 [/SUP], Antonietta M Lillo[SUP] 1 [/SUP], Andrew R M Bradbury[SUP] 2 [/SUP]



Affiliations

Abstract

Interactions between the cytoplasmic domains of viral transmembrane proteins and host machinery often determine the outcome of viral infection. The M2 protein of influenza A has been identified as a key player in autophagy-mediated viral replication. Here, we describe the engineering and validation of an antibody specific for the cytoplasmic domain of the M2 protein. Through phage and yeast display selection techniques, we obtained an antibody that recognizes: 1) the M2 cytoplasmic domain purified from bacterial inclusion bodies and refolded, 2) full-length M2 recombinant protein expressed in mammalian cells, and 3) native M2 protein in influenza A infected cells. This antibody can serve as a molecular tool to enhance our knowledge of protein-protein interactions between influenza A virus and the host cell machinery. We anticipate the methods described herein will further the development of antibodies specific to the cytoplasmic domains of transmembrane proteins.

Keywords: Influenza A; M2 cytoplasmic domain; antibodies; antibody formats; phage display; transmembrane proteins; yeast display.
 
Back
Top Bottom